QuidelOrtho reported a 10.5% revenue decline to $620 million in Q1 2026, driven by a weak respiratory season and disruptions in China and the Middle East. The company posted a GAAP net loss of $92 million but highlighted growth in immunohematology and completed the LEX Diagnostics acquisition to boost molecular diagnostics. It lowered its full-year 2026 revenue and earnings guidance due to ongoing market challenges and pending China pricing guideline changes. QuidelOrtho remains focused on expanding margins and cash flow with new product launches in the U.S. and international markets.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...
Natural Grocers, a leading organic grocery retailer, is opening its first store in Wisconsin on June 10, 2026, in Lake Geneva. The grand opening will feature giveaways, discounts, a prize wheel, and a $2,500 donation to the Lake Geneva Food Pantry, h...
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
